ImmunityBio Inc (IBRX)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet

Issued on behalf of GT Biopharma, Inc. (Nasdaq: GTBP) A clinical-stage immuno-oncology company has moved three...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026

Presentations highlight ANKTIVA®-based approaches in non-small cell lung cancer (NSCLC) and non-muscle invasive bladder cancer (NMIBC...

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026...

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc...

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

Analysis demonstrates a lower cost per sustained responder and cystectomy avoided with ANKTIVA plus BCG compared to TAR-200 in Medicare...